Problem

Ritivel addresses the slow, labor-intensive process of preparing regulatory submissions in life sciences. Regulatory and medical-writing teams must synthesize thousands of pages of clinical data, locate the right files across internal repositories, chase missing inputs, and manually draft documents such as Clinical Study Reports (CSRs), CTDs, INDs, and BLAs. Ritivel says that each month a drug is delayed can cost a pharmaceutical company approximately $45 million in lost revenue, while also delaying treatment for patients.

The clearest use case is automating Clinical Study Report production, particularly the conversion of a clinical protocol and Statistical Analysis Plan into a complete, submission-ready CSR. This targets a recurring, document-heavy bottleneck where faster drafting can reduce review cycles and help therapies reach patients sooner.

Product / Service

Ritivel is an AI-native regulatory workspace for pharmaceutical, biotech, medtech, CRO, and related life-sciences teams. Its AI agents draft CTDs, CSRs, INDs, BLAs, and other regulatory documents in minutes rather than weeks, using clinical data, prior submissions, and connected repositories such as SharePoint and Veeva. The company positions the platform as an enterprise-oriented service demonstrated through live walkthroughs and tailored workflow discussions, rather than as a self-serve commodity writing tool.

Its CSR workflow takes a clinical protocol and SAP, drafts the non-data sections, performs post-data-lock biostatistical analysis, generates Tables, Listings, and Figures, and converts those outputs into the document's data-centric narrative sections. The key benefits are reproducibility, domain-specific language understanding, and word-level traceability from claims and numbers back to source material. Ritivel also emphasizes local deployment, no cloud storage, zero data retention, and keeping customer documents within the customer's infrastructure.

Market

Ritivel competes in life-sciences regtech and AI-enabled regulatory-documentation and medical-writing software. Its closest competitive context includes Veeva Vault/Submissions for regulatory content management, Certara's CoAuthor for automated regulatory writing, and regulatory consulting and software providers such as PAREXEL and Certara. Other possible AI-oriented alternatives include newer pharma-documentation entrants, while Ritivel differentiates around Word-native drafting, source traceability, reproducible outputs, and integrations with existing enterprise repositories.

The company appears to be an early-stage, actively commercializing startup rather than a mature incumbent. It was founded in 2025, is an active Y Combinator Winter 2026 company, reports more than 50 conversations with pharma professionals during discovery, and has a live Regulatory Search demo. Public databases report $500,000 of funding from Y Combinator, but there are no publicly named customer logos or pricing, and current revenue is not clearly disclosed: one database labels the financing-stage status "Generating Revenue" while leaving the current-revenue field blank. The most defensible characterization is therefore early commercial traction with revenue status undisclosed, not definitively pre-revenue.